MX2020002984A - Anticuerpos de cd40 agonistas. - Google Patents
Anticuerpos de cd40 agonistas.Info
- Publication number
- MX2020002984A MX2020002984A MX2020002984A MX2020002984A MX2020002984A MX 2020002984 A MX2020002984 A MX 2020002984A MX 2020002984 A MX2020002984 A MX 2020002984A MX 2020002984 A MX2020002984 A MX 2020002984A MX 2020002984 A MX2020002984 A MX 2020002984A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- present
- epitope
- compositions
- receptor
- Prior art date
Links
- 230000001270 agonistic effect Effects 0.000 title 1
- 101150013553 CD40 gene Proteins 0.000 abstract 3
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 108010029697 CD40 Ligand Proteins 0.000 abstract 1
- 102100032937 CD40 ligand Human genes 0.000 abstract 1
- 101000924577 Homo sapiens Adenomatous polyposis coli protein Proteins 0.000 abstract 1
- 101100099884 Homo sapiens CD40 gene Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000004132 cross linking Methods 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 102000055691 human APC Human genes 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a anticuerpos monoclonales humanizados o fragmentos de unión a antígeno de los mismos que se unen específicamente al receptor de CD40 de humano e inducen la señalización de CD40 independiente del entrelazamiento del receptor de CD40 mediado por Fc?. Los anticuerpos de la presente invención se unen a un epítope de CD40 que se traslapa con el epítope del ligando de CD40 y pueden activar las APC de humano. La presente invención también provee composiciones que comprenden dichos anticuerpos y usos para los anticuerpos y composiciones en el tratamiento de pacientes que padecen de cáncer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17191974 | 2017-09-19 | ||
| PCT/EP2018/075388 WO2019057792A1 (en) | 2017-09-19 | 2018-09-19 | CD40 ANTIBODY AGONISTS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002984A true MX2020002984A (es) | 2020-07-22 |
Family
ID=59914405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002984A MX2020002984A (es) | 2017-09-19 | 2018-09-19 | Anticuerpos de cd40 agonistas. |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11702478B2 (es) |
| EP (1) | EP3684813A1 (es) |
| JP (2) | JP7346390B2 (es) |
| KR (1) | KR20200063139A (es) |
| CN (2) | CN111225924B (es) |
| AU (1) | AU2018335828A1 (es) |
| BR (1) | BR112020003988A2 (es) |
| CA (1) | CA3075221A1 (es) |
| EA (1) | EA202090791A1 (es) |
| IL (1) | IL272770A (es) |
| MX (1) | MX2020002984A (es) |
| SG (1) | SG11202002366VA (es) |
| WO (1) | WO2019057792A1 (es) |
| ZA (1) | ZA202001066B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3158527A1 (en) * | 2019-10-23 | 2021-04-29 | Lyvgen Biopharma Holdings Limited | Anti-cd40 binding molecules and bi-specific antibodies comprising such |
| CN113861292A (zh) * | 2020-06-30 | 2021-12-31 | 百奥泰生物制药股份有限公司 | 抗cd40抗体或抗原结合片段及其应用 |
| WO2023052581A1 (en) * | 2021-10-01 | 2023-04-06 | Mab Discovery Gmbh | Agonistic cd40 antibodies as immune stimulatory agents |
| KR20240003755A (ko) * | 2022-06-29 | 2024-01-09 | 고려대학교 산학협력단 | 인간 FcγRs 결합력이 제거된 당화 Fc 변이체들 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE374214T1 (de) * | 2001-04-27 | 2007-10-15 | Kirin Brewery | Monoklonaler anti-cd-40-antikörper |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| US7563443B2 (en) * | 2004-09-17 | 2009-07-21 | Domantis Limited | Monovalent anti-CD40L antibody polypeptides and compositions thereof |
| UA106070C2 (uk) | 2009-03-20 | 2014-07-25 | Дженентек, Інк. | Антитіло, що специфічно зв'язується з egfr і her3 |
| AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
| ES2709654T3 (es) | 2011-04-29 | 2019-04-17 | Apexigen Inc | Anticuerpos anti-CD40 y métodos de uso |
| GB201115280D0 (en) | 2011-09-05 | 2011-10-19 | Alligator Bioscience Ab | Antibodies, uses and methods |
| WO2015145360A1 (en) | 2014-03-24 | 2015-10-01 | Glennie Martin J | Modified antibodies containing modified igg2 domains which elicit agonist or antagonistic properties and use thereof |
| MX2017016502A (es) | 2015-06-29 | 2018-03-12 | Univ Rockefeller | Anticuerpos contra cd40 con actividad agonista mejorada. |
| GB201601073D0 (en) * | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
| EA037882B1 (ru) | 2015-09-30 | 2021-05-31 | Янссен Байотек, Инк. | Агонистические антитела, специфически связывающие человеческий cd40, и способы их применения |
| SG11201808821WA (en) | 2016-04-18 | 2018-11-29 | Celldex Therapeutics Inc | Agonistic antibodies that bind human cd40 and uses thereof |
| CA3030636A1 (en) * | 2016-07-14 | 2018-01-18 | Genmab A/S | Multispecific antibodies against cd40 and cd137 |
| EP3401332A1 (en) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
-
2018
- 2018-09-19 EP EP18778857.5A patent/EP3684813A1/en active Pending
- 2018-09-19 JP JP2020515887A patent/JP7346390B2/ja active Active
- 2018-09-19 WO PCT/EP2018/075388 patent/WO2019057792A1/en unknown
- 2018-09-19 CA CA3075221A patent/CA3075221A1/en active Pending
- 2018-09-19 US US16/648,731 patent/US11702478B2/en active Active
- 2018-09-19 BR BR112020003988-8A patent/BR112020003988A2/pt unknown
- 2018-09-19 SG SG11202002366VA patent/SG11202002366VA/en unknown
- 2018-09-19 AU AU2018335828A patent/AU2018335828A1/en active Pending
- 2018-09-19 MX MX2020002984A patent/MX2020002984A/es unknown
- 2018-09-19 CN CN201880060719.0A patent/CN111225924B/zh active Active
- 2018-09-19 CN CN202311296534.9A patent/CN117551197A/zh active Pending
- 2018-09-19 KR KR1020207007613A patent/KR20200063139A/ko not_active Application Discontinuation
- 2018-09-19 EA EA202090791A patent/EA202090791A1/ru unknown
-
2020
- 2020-02-19 ZA ZA2020/01066A patent/ZA202001066B/en unknown
- 2020-02-19 IL IL272770A patent/IL272770A/en unknown
-
2023
- 2023-05-25 US US18/323,757 patent/US20240010741A1/en active Pending
- 2023-09-06 JP JP2023144799A patent/JP2023182583A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3684813A1 (en) | 2020-07-29 |
| JP2023182583A (ja) | 2023-12-26 |
| CN111225924A (zh) | 2020-06-02 |
| ZA202001066B (en) | 2021-09-29 |
| CA3075221A1 (en) | 2019-03-28 |
| US11702478B2 (en) | 2023-07-18 |
| SG11202002366VA (en) | 2020-04-29 |
| JP7346390B2 (ja) | 2023-09-19 |
| KR20200063139A (ko) | 2020-06-04 |
| US20240010741A1 (en) | 2024-01-11 |
| JP2020534292A (ja) | 2020-11-26 |
| CN111225924B (zh) | 2023-10-10 |
| IL272770A (en) | 2020-04-30 |
| US20200239583A1 (en) | 2020-07-30 |
| BR112020003988A2 (pt) | 2020-09-01 |
| WO2019057792A1 (en) | 2019-03-28 |
| EA202090791A1 (ru) | 2020-06-17 |
| CN117551197A (zh) | 2024-02-13 |
| AU2018335828A1 (en) | 2020-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GEP20227440B (en) | Anti-ilt4 antibodies and antigen-binding fragments | |
| ZA201803079B (en) | Anti-dr5 antibodies and methods of use thereof | |
| MX2020002984A (es) | Anticuerpos de cd40 agonistas. | |
| MX2018012757A (es) | Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos. | |
| MX2020012567A (es) | Anticuerpos anti-ox40 y metodos de uso. | |
| MX2018006925A (es) | Anticuerpos monoclonales anti-ctla4 humano quimericos y humanizados y sus usos. | |
| EA201792221A1 (ru) | Антитела против сортилина и способы их применения | |
| MX2022004072A (es) | Anticuerpos de factor xi y metodos de uso. | |
| PH12017500229A1 (en) | Combination therapies with anti cd40 antibodies | |
| PH12018550179A1 (en) | Anti-pd-1 antibodies, method for producing same and method for using same | |
| MX2017014188A (es) | Anticuerpos anti-ox40 y metodos para su uso. | |
| MX2018008995A (es) | Combinacion de un agonista de ox40 y un agonista de 4-1bb para tratar el cancer. | |
| GEP20207166B (en) | Anti-ctla4 monoclonal antibody or antigen-binding fragment thereof, medicinal composition and use | |
| MX2018012473A (es) | Agentes que reconocen el epitopo de clever-1 y usos de los mismos. | |
| MX2019009498A (es) | Anticuerpos mimeticos de fgf21 y usos de los mismos. | |
| PH12020550825A1 (en) | Anti-c5 antibody combinations and uses thereof | |
| PH12020552006A1 (en) | Antibodies specific for cd3 and uses thereof | |
| WO2018175279A3 (en) | MITIGATING Fc-Fc RECEPTOR INTERACTIONS IN CANCER IMMUNOTHERAPY | |
| EA202190183A1 (ru) | Антитела к siglec-5 и способы их применения | |
| PH12020552235A1 (en) | Anti-cd40 antibodies for use in treating autoimmune disease | |
| ZA202008095B (en) | Humanized antibodies against psma | |
| MX2023004314A (es) | Anticuerpos ligando anti grupo de diferenciacion 40 (cd40) terapeuticos. | |
| MX2021003168A (es) | Anticuerpo anti-ox40, fragmento de union al antigeno del mismo y uso farmaceutico. | |
| MX2020002750A (es) | Anticuerpo il-6r y fragmento de union a antigeno y uso medico. | |
| EP3735423A4 (en) | NEO-201 MONOCLONAL ANTIBODY FOR TREATMENT OF HUMAN CARCINOMA |